Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a single-arm, single-centre phase II study to evaluate the efficacy (PFS, ORR, DCR)
and safety of recombinant human adenovirus type 5 in combination with tirelizumab and
platinum-containing dual-agent chemotherapy in previously untreated patients with advanced
non-small cell lung cancer who are EGFR/ALK negative. The study is divided into 2 phases.